Alnylam Pharmaceuticals, Inc., 10% Owner at Regulus Therapeutics Inc. (RGLS), sold 7,700 shares at $7.22 ($56K) on 2014-09-19, disclosed to the SEC on 2014-09-19.
Scheduled sale ($56k) by 10% Owner under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $7.43 | 2,100 | $16K | 27.7% |
| 2 | $7.40 | 1,500 | $11K | 19.7% |
| 3 | $7.22 | 4,100 | $30K | 52.6% |
| Total | $7.31 avg | 7,700 | $56K | 100% |
| Filing → |
| RGLS | SELL | 2014-10-24 | $1.6M | — | Filing → |
| RGLS | SELL | 2014-10-17 | $81K | — | Filing → |
| RGLS | SELL | 2014-10-10 | $66K | — | Filing → |